Physician profile
Billy T Hour
NPI 1790097004
$3,320.96
in general payments reported to CMS, 2019-2025
34 companies · $644 in 2025
The $644 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $278 · 2021: $447 · 2022: $204 · 2023: $531 · 2024: $525 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699 · Education: $0.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.45 |
| Education | $0.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $566.64 | 2023-2025 | Benlysta, Jesduvroq |
| Amgen INC. | $549.05 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $409.88 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $369.97 | 2019-2021 | |
| Horizon Therapeutics Plc | $187.85 | 2019-2023 | Krystexxa |
| Cardiovascular Systems INC. | $159.50 | 2019 | |
| Mallinckrodt Hospital Products INC. | $153.40 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $142.94 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $142.00 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $112.69 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.77 | 2025 | Jardiance |
| Travere Therapeutics, INC. | $64.55 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $53.93 | 2023 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $50.98 | 2023-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $50.04 | 2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $45.11 | 2019 | |
| Akebia Therapeutics INC | $41.85 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $27.84 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.37 | 2024 | |
| Alexion Pharmaceuticals, INC. | $23.00 | 2019 | |
| Fresenius USA Marketing, INC. | $19.98 | 2020 | |
| La Jolla Pharmaceutical Company | $18.22 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.89 | 2019 |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Hour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.